Molecular Partners’ collaboration partner Allergan has exercised the third option to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners.
Molecular Partners reports its unaudited financial results for 2017, a year marked by promising clinical data in oncology as well as the successful, early completion of patient recruitment for phase 3 studies of abicipar.
Molecular Partners announced initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (MM).
Molecular Partners presents at the 36th Annual J.P. Morgan Healthcare Conference.
Molecular Partners announced that Allergan has exercised two options to develop and commercialize DARPin® product candidates from its 2012 discovery alliance agreement with Molecular Partners.
Molecular Partners holds its R&D update in New York, entitled “The DARPin® Difference – Offering Patients a New Dimension of Protein Therapeutics”, which features a series of presentations highlighting the scientific rationale and the potential clinical impact of the DARPin® approach, as well as the company’s continued forward integration and evolution towards becoming a fully integrated biopharmaceutical company.
At the EGM the shareholders of Molecular Partners approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals, and Patrick Amstutz, CEO of Molecular Partners, as new members of the Board of Directors with large majorities.
Molecular Partners announced its Interim Management Statement for the period ending September 30, 2017.
The first patient was dosed in the phase 1 clinical study of Molecular Partners’ oncology asset MP0274, a proprietary DARPin® drug candidate for the treatment of HER2-positive cancer with a new mode of action compared to current standard of care antibodies.
Molecular Partners published the invitation to EGM on October 31, 2017.